Novo Nordisk (NVO) Q1 Earnings Beat, GLP-1 Drugs Boost Sales

Novo Nordisk A/S (NVO) reported first-quarter 2024 earnings of 83 cents per American Depositary Receipt (ADR), which surpassed the Zacks Consensus Estimate of 77 cents. The company had reported earnings of 63 cents per ADR in the year-ago quarter.Revenues of $9.52 billion increased 22% in Danish kroner (DKK) and were up 24% at constant exchange rate (CER) in the reported quarter. Total revenues also beat the Zacks Consensus Estimate of$ 9.23 billion. The year-over-year increase in revenues was driven by hig ...